
Piramal Pharma Acquires Yapan Bio
Piramal Pharma strengthens its biologics CDMO business, converting Yapan Bio from associate company to subsidiary and expanding vaccine and biologics manufacturing capabilities.

Piramal Pharma strengthens its biologics CDMO business, converting Yapan Bio from associate company to subsidiary and expanding vaccine and biologics manufacturing capabilities.

Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.

US contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS), part of India-headquartered Piramal Pharma, plans to invest $80 million for the expansion of its Lexington, Kentucky, facility.

